X-Rx announces FDA acceptance of IND for X-165, a potential treatment for Idiopathic Pulmonary Fibrosis
US-based biotech company X-Rx has received a major boost in its quest to develop new treatments for Idiopathic Pulmonary Fibrosis (IPF) with the US Food and Drug Administration (FDA) accepting its Investigational New Drug (IND) application for X-165, an innovative small molecule inhibitor of Autotaxin. This approval opens the door to clinical trials for X-165, […]